Zenbexus (iberdomide) NDC 0003-5700

NDC codes

FDA NDC Directory

Product NDC (as listed)0003-5700Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00003-5700Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0003-5700-21	00003570021	21 CAPSULE in 1 BOTTLE (0003-5700-21)Marketed from Aug 13, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zenbexus
Generic name (nonproprietary): iberdomide
Active ingredients: Iberdomide hydrochloride — .75 mg/1
Dosage form: Capsule
Route: Oral
Labeler: E.R. Squibb & Sons, L.L.C.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 221075
Marketing start: Aug 13, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 0003-5700_05b6e27f-40ba-4939-a0c3-8e8ae1feae98SPL ID 05b6e27f-40ba-4939-a0c3-8e8ae1feae98SPL set ID 3663d9cb-3f66-48ae-bf0a-6958bc0888deRxCUI 2749737, 2749743, 2749745, 2749747UNII 79L3645KFI

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400003570021 followed by a unit qualifier and the quantity

Package 00003-5700-21. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 13, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZENBEXUS is a cereblon-modulating protein degrader indicated in combination with daratumumab and hyaluronidase-fihj and d…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 221075

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 221075
Product	Strength	Form · route	Labeler	Product NDC
Zenbexusiberdomide	Iberdomide hydrochloride 1 mg/1	CapsuleOral	E.R. Squibb & Sons, L.L.C.	0003-5710